Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

AlloVir, Inc. ALVR NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
47/100
1/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

AlloVir, Inc. (ALVR) is a Biotechnology company in the Healthcare sector, currently trading at $9.81. It has a SharesGrow Score of 44/100, indicating a mixed investment profile with 1 out of 7 criteria passed.

Net income is $43M (loss), growing at +27.5%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $1M against $79M equity (Debt-to-Equity (D/E) ratio 0.02, conservative). Current ratio is 12.23 (strong liquidity). Debt-to-assets is 1.2%. Total assets: $122M.

Analyst outlook: 4 / 8 analysts rate ALVR as buy (50%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 100/100 (Pass), Past 0/100 (Fail), Health 67/100 (Partial), Moat 28/100 (Fail), Future 40/100 (Partial), Income ?/100 (Fail).

ALVR SharesGrow Score Overview

59/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 100/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 40/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ALVR

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✓
GROWTH Pass
100/100
ALVR: +0%/yr revenue is, +27.5%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet ALVR: Debt-to-Equity (D/E) ratio 0.02 (conservative), Current ratio is 12.23 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
ALVR: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
40/100
Analyst outlook: 4 / 8 analysts rate ALVR as buy (50%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range7.96-24.15
Volume9.4K
Avg Volume (30D)22.94K
Market Cap$49.48M
Beta (1Y)0.62
Share Statistics
EPS (TTM)-2.85
Shares Outstanding$152.68M
IPO Date2020-07-30
Employees6
CEOVikas Sinha CPA,
Financial Highlights & Ratios
EBITDA$-46.15M
Net Income$-43.44M
Operating Income$-46.15M
Total Cash$117.98M
Total Debt$1.45M
Net Debt$-96.61M
Total Assets$121.74M
Price / Earnings (P/E)-3.4
Analyst Forecast
Rating ConsensusBuy
Analysts Covering8
Buy 50% Hold 25% Sell 25%
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS4829291065

Price Chart

Track all markets on TradingView
ALVR
AlloVir, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
7.96 52WK RANGE 24.15

People Also View

MRUS
MRUS
Merus N.V.
$90.00
+0.00%
 CRNX
CRNX
Crinetics Pharmaceuticals, Inc.
$39.75
+2.82%
 STOK
STOK
Stoke Therapeutics, Inc.
$35.86
+2.31%
 ANAB
ANAB
AnaptysBio, Inc.
$70.22
+2.17%
 AGIO
AGIO
Agios Pharmaceuticals, Inc.
$33.30
+0.45%
 MLYS
MLYS
Mineralys Therapeutics, Inc.
$27.32
+0.59%
 INBX
INBX
Inhibrx Biosciences, Inc.
$83.19
+7.40%
 CGEM
CGEM
Cullinan Oncology, Inc.
$14.35
+0.70%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message